Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 6Thoracic 3Gastrointestinal 3Breast 3Gynecologic 1

Conditions

Colorectal Neoplasms 408Rectal Neoplasms 152Colonic Neoplasms 150Pancreatic Neoplasms 114Stomach Neoplasms 110Neoplasm Metastasis 70Esophageal Neoplasms 60Esophageal Squamous Cell Carcinoma 33Neoplasms 31Adenocarcinoma Of Esophagus 27Gastrointestinal Neoplasms 17Cholangiocarcinoma 14Biliary Tract Neoplasms 14Gallbladder Neoplasms 12Carcinoma, Hepatocellular 12Adenocarcinoma 12Colorectal Cancer Metastatic 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Liver Neoplasms 10Digestive System Neoplasms 10Ovarian Neoplasms 9Small Cell Lung Carcinoma 8Locally Advanced Rectal Cancer 8Intestinal Neoplasms 8Bile Duct Neoplasms 8Carcinoma 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Digestive System Diseases 6Appendiceal Neoplasms 6

Interventions

pembrolizumab 29Cetuximab 11Nivolumab 10Fluorouracil 8Cyclophosphamide 8Cisplatin 8Carboplatin 8fludarabine 7atezolizumab 7Blood Specimen Collection 7cemiplimab 6Radiotherapy 6Drug Therapy 6Immune Checkpoint Inhibitors 5Gemcitabine 5Paclitaxel 4Docetaxel 4Capecitabine 4Biopsy 4spartalizumab 3avelumab 3Surveys and Questionnaires 3Pemetrexed 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Ipilimumab 3Interleukin-2 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Irinotecan × Gastrointestinal × Clear all
NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

SN BioScience

Phase 1 Completed
21 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT01520389 2018-03-21

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Merrimack Pharmaceuticals

Phase 1 Completed
112 enrolled
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡